Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Perspective Therapeutics (CATX) Current Deferred Revenue (2024)

Historic Current Deferred Revenue for Perspective Therapeutics (CATX) over the last 1 years, with Q4 2024 value amounting to $1.4 million.

Perspective Therapeutics' Current Deferred Revenue changed N/A to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2024, which is N/A changed from last year.
As of Q4 2024, Perspective Therapeutics' Current Deferred Revenue stood at $1.4 million.
Perspective Therapeutics' Current Deferred Revenue's 5-year high stood at $1.4 million during Q1 2024, with a 5-year trough of $1.4 million in Q1 2024.